open access

Vol 13, No 4 (2017)
Case report
Published online: 2017-09-13
Get Citation

Giant-cell tumour of bone with lung metastases — case report

Katarzyna Gabalewicz, Emilia Filipczyk- Cisarż
DOI: 10.5603/OCP.2017.0020
·
Oncol Clin Pract 2017;13(4):169-171.

open access

Vol 13, No 4 (2017)
CASE REPORTS
Published online: 2017-09-13

Abstract

Giant cell tumor of bone is usually a benign neoplasm with local malignant potential. In some cases it could be more aggressive and treatment is not always effective. The individual strategy could be beneficial and different therapeutic methods worth to use such, as bone remodeling substances, chemotherapy, radiotherapy and maybe in the future immunotherapy.

Abstract

Giant cell tumor of bone is usually a benign neoplasm with local malignant potential. In some cases it could be more aggressive and treatment is not always effective. The individual strategy could be beneficial and different therapeutic methods worth to use such, as bone remodeling substances, chemotherapy, radiotherapy and maybe in the future immunotherapy.

Get Citation

Keywords

tumor gigantocellularis, giant cell tumor,lung metastasis, denosumab, chemotherapy, radiotherapy abscopal effect

About this article
Title

Giant-cell tumour of bone with lung metastases — case report

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 4 (2017)

Article type

Case report

Pages

169-171

Published online

2017-09-13

DOI

10.5603/OCP.2017.0020

Bibliographic record

Oncol Clin Pract 2017;13(4):169-171.

Keywords

tumor gigantocellularis
giant cell tumor
lung metastasis
denosumab
chemotherapy
radiotherapy abscopal effect

Authors

Katarzyna Gabalewicz
Emilia Filipczyk- Cisarż

References (12)
  1. Beebe-Dimmer JL, Cetin K, Fryzek JP, et al. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004). Rare Tumors. 2009; 1(2): e52.
  2. Klenke FM, Wenger DE, Inwards CY, et al. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011; 469(2): 591–599.
  3. Singh AS, Chawla NS, Chawla SP. Giant-cell tumor of bone: treatment options and role of denosumab. Biologics. 2015; 9: 69–74.
  4. López-Pousa A, Martín Broto J, Garrido T, et al. Giant cell tumour of bone: new treatments in development. Clin Transl Oncol. 2015; 17(6): 419–430.
  5. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The Lancet Oncology. 2010; 11(3): 275–280.
  6. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013; 14(9): 901–908.
  7. Xu SF, Adams B, Yu XC, et al. Denosumab and giant cell tumour of bone—a review and future management considerations. Curr Oncol. 2013; 20(5): 442.
  8. Skubitz KM. Giant cell tumor of bone: current treatment options. Curr Treat Options Oncol. 2014; 15(3): 507–518.
  9. Yasko A. Interferon therapy for giant cell tumor of bone. Curr Opin Orthop. 2006; 17(6): 568–572.
  10. Kaban L, Troulis M, Ebb D, et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. Journal of Oral and Maxillofacial Surgery. 2002; 60(10): 1103–1111.
  11. Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med. 2016; 4(6): 118.
  12. Johnson CB, Jagsi R. The promise of the abscopal effect and the future of trials combining immunotherapy and radiation therapy. Int J Radiat Oncol Biol Phys. 2016; 95(4): 1254–1256.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl